A Pilot Study of Shortened Induction Chemotherapy for Children with High-Risk Neuroblastoma

Share
Print

Full Title

N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma

Purpose

The purpose of this study is to assess a new combination of chemotherapy drugs as the first treatment for children newly diagnosed with neuroblastoma that has a high risk of returning after therapy. The treatment is abbreviated N9 and includes three different drug combinations given at three different times:

  • Cyclophosphamide, topotecan, and vincristine
  • Ifosfamide, carboplatin, and etoposide 
  • Cyclophosphamide, doxorubicin, and vincristine 

The number of different drugs in N9 may make it less likely that the cancer will become resistant to chemotherapy. In addition, researchers think that N9 may have fewer side effects than the usual treatment approach.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have high-risk neuroblastoma that has not yet been treated with chemotherapy.
  • This study is for patients older than 1 year and younger than 13.

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.

Protocol

21-228

Investigator

Co-Investigators